Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 641-647

  Peceliunas, Valdas ^a,b   Janiulioniene, Ausra ^c   Matuzeviciene, Reda ^c   Zvirblis, Tadas ^a   Griskevicius, Laimonas ^a,b  

^a Hematology Oncology and Transfusion Medicine Center   (Lithuania)

^b Family Medicine and Oncology   (Lithuania)

^c VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Circulating plasma cells; Flow cytometry; Myeloma; Prognosis

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CELL KINETICS; CIRCULATING PLASMA CELL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOTHESIS; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHENOTYPE; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEOPLASTIC CELLS, CIRCULATING; PLASMA CELLS; PROGNOSIS; PROSPECTIVE STUDIES; PYRAZINES; RECURRENCE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859090818     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.627481     Document Type: Article

References (35)

1. Harousseau JL, Attal M, Avet-Loiseau H. Th e role of complete response in multiple myeloma. Blood 2009;114:3139-3146.
2. van de Velde HJ, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92:1399-1406.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
4. Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001;27:1037-1043.
5. Blade J, Esteve J, Rives S, et al. High-dose therapy autotransplantation/ intensifi cation vs continued standard chemotherapy in multiple myeloma in fi rst remission. Results of a nonrandomized study from a single institution. Bone Marrow Transplant 2000;26:845-849.
6. O ' Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006;37:731-737.
7. Wang M, Delasalle K, Th omas S, et al. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 2006;108(Suppl. 1): Abstract 403.
8. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434-2441.
9. Harousseau J-L, Weber D, Dimopoulos M, et al. Relapsed/refractory multiple myeloma patients treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial response. Blood 2007;110(Suppl. 1): Abstract 3598.
10. Niesvizky R, Richardson PG, Rajkumar SV, et al. Th e relationship between quality of response and clinical benefi t for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 2008;143: 46-53.
11. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
12. Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431-438.
13. van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy defi ne an aggressive multiple myeloma subtype with poor prognosis. Blood 2007;110:827-832.
14. Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008;111:4908-4915.
15. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23: 215-224.
16. Morice WG, Hanson CA, Kumar S, et al. Novel multi-parameter fl ow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia 2007;21:2043-2046.
17. de Tute RM, Jack AS, Child JA, et al. A single-tube six-colour fl ow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia 2007;21:2046-2049.
18. Mason KD, Juneja S. Go with the fl ow for monitoring response in myeloma with minimal residual disease. Leuk Lymphoma 2008;49:177-178.
19. Witzig TE, Gertz MA, Lust JA, et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996;88:1780-1787.
20. Dingli D, Nowakowski GS, Dispenzieri A, et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratifi cation system. Blood 2006;107:3384-3388.
21. Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by fl ow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005;106: 2276-2279.
22. Pardanani A, Witzig TE, Schroeder G, et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003;101:827-830.
23. Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined signifi cance. J Clin Oncol 2005;23:5668-5674.
24. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997;97:46-55.
25. Rawstron AC. Immunophenotyping of plasma cells. Curr Protoc Cytom 2006;Chapter 6:Unit6.23.
26. Manzanera GM, San Miguel Izquierdo JF, Matos AO. Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 2005;113:5-24.
27. Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121:482-488.
28. Pellat-Deceunynck C, Bataille R. Normal and malignant human plasma cells: proliferation, diff erentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis 2004;32:293-301.
29. Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999;107:121-131.
30. Subira D, Castanon S, Aceituno E, et al. Flow cytometric analysis of cerebrospinal fl uid samples and its usefulness in routine clinical practice. Am J Clin Pathol 2002;117:952-958.
31. Peceliunas V, Janiulioniene A, Matuzeviciene R, et al. Six color fl ow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin Cytom 2011 Apr 6. [Epub ahead of print]
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
33. Witzig TE, Kimlinger TK, Ahmann GJ, et al. Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 1996;26:113 -1 20.
34. Witzig TE, Kyle RA, O ' Fallon WM, et al. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol 1994;87:266-272.
35. Kumar S, Witzig TE, Greipp PR, et al. Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. Br J Haematol 2003;122:272-274.